Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer | Zendy

Christopher J. Sweeney | Zendy; YuHui Chen | Zendy; Michael A. Carducci | Zendy; Glenn Liu | Zendy; David F. Jarrard | Zendy; Mario A. Eisenberger | Zendy; Yu-Ning Wong | Zendy; Noah M. Hahn | Zendy; Manish Kohli | Zendy; Matthew M. Cooney | Zendy; Robert Dreicer | Zendy; Nicholas J. Vogelzang | Zendy; Joel Picus | Zendy; Daniel H. Shevrin | Zendy; Maha Hussain | Zendy; Jorge A. García | Zendy; Robert S. DiPaola | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Author(s) -

Christopher J. Sweeney,

YuHui Chen,

Michael A. Carducci,

Glenn Liu,

David F. Jarrard,

Mario A. Eisenberger,

Yu-Ning Wong,

Noah M. Hahn,

Manish Kohli,

Matthew M. Cooney,

Robert Dreicer,

Nicholas J. Vogelzang,

Joel Picus,

Daniel H. Shevrin,

Maha Hussain,

Jorge A. García,

Robert S. DiPaola

Publication year - 2015

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1503747

Subject(s) - androgen deprivation therapy , prostate cancer , docetaxel , concomitant , oncology , medicine , hormone therapy , cancer , breast cancer

Androgen-deprivation therapy (ADT) has been the backbone of treatment for metastatic prostate cancer since the 1940s. We assessed whether concomitant treatment with ADT plus docetaxel would result in longer overall survival than that with ADT alone.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research